Altimmune
ALT
28 hedge funds and large institutions have $2.44M invested in Altimmune in 2019 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 8 closing their positions.
12% more capital invested
Capital invested by funds: $2.18M → $2.44M (+$252K)
1.18% more ownership
Funds ownership: 7.27% → 8.46% (+1.2%)
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
7% less funds holding
Funds holding: 30 → 28 (-2)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$240K |
| 2 |
WG
Winton Group
London,
United Kingdom
|
+$82.5K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$66.7K |
| 4 |
Allianz Asset Management
Munich,
Germany
|
+$28.1K |
| 5 |
CG
Caprock Group
Boise,
Idaho
|
+$28.1K |
Top Sellers
| 1 |
ARTA
A.R.T. Advisors
New York
|
-$55K |
| 2 |
VF
Virtu Financial
New York
|
-$28K |
| 3 |
SG Americas Securities
New York
|
-$25K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$22.3K |
| 5 |
Squarepoint
New York
|
-$22K |
ALT Hedge Fund Activity: Q4 2019 in Review
28 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q4 2019, worth a combined $2.44M — up 12% from $2.18M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ALT and 6 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, adding an estimated $240K. The largest seller was A.R.T. Advisors, exiting entirely with an estimated $55K sold.
- 28 institutional investors held Altimmune (ALT) as of Q4 2019, down from 30 in Q3 2019.
- Funds reported $2.44M of Altimmune stock for Q4 2019, up 12% quarter-over-quarter.
- 6 funds opened new Altimmune positions in Q4 2019 and 8 closed out, a net change of -2 holders.
- The largest Altimmune buyer in Q4 2019 was Renaissance Technologies, an estimated $240K added.
- The largest Altimmune seller in Q4 2019 was A.R.T. Advisors, an estimated $55K sold.
Based on aggregated 13F filings for Q4 2019.